Ikonisys SA: Terms and Conditions of Availability of Preparatory Documents for the General Meeting of June 28, 2023
14 Juin 2023 - 6:33PM
Business Wire
Regulatory News:
Ikonisys SA (ISIN Code: FR00140048X2 / Mnemonic: ALIKO),
a company specializing in the early and accurate detection of
cancer with a unique and fully-automated solution for medical
diagnostic labs, today announces that the preparatory documents for
the General Meeting of June 28, 2023 will be made available to the
public. The meeting will be held at 2.30 pm at the offices of the
Jeantet law firm, 11, street Galilée - 75116 Paris.
The notice of meeting serving as a notice of meeting including
the agenda as well as the procedures for participating in and
voting at the Meeting was published in the Bulletin of Legal
Announcements (BALO) on May 24, 2023.
Documents and information relating to the Combined General
Meeting, as well as the single voting form, are available on the
Company's website, in the "Shareholders" section.
Any shareholder may obtain the documents referred to above under
the conditions set out in Articles R.225-88 and R.225-89 of the
Commercial Code by sending a written request to the Company's
registered office at 62 RUE DE CAUMARTIN, 75009 PARIS.
Shareholders may vote :
- in person on the day of the General Meeting with an admission
card;
- by post ;
- or by proxy.
About Ikonisys Ikonisys SA is a cell-based diagnostics
company based in Paris (France), New Haven (Connecticut, USA) and
Milan (Italy) specialized in the early and accurate detection of
cancer. The company develops, produces and markets the proprietary
Ikoniscope20® platform, a fully-automated solution designed to
deliver accurate and reliable detection and analysis of rare and
very rare cells. Ikonisys has received FDA clearance for several
automated diagnostic applications, which are also marketed in
Europe under CE certification. Through its breakthrough
fluorescence microscopy platform, the company continues to develop
a stream of new tests, including liquid biopsy tests based on
Circulating Tumor Cells (CTC).
For further information, please go to www.Ikonisys.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230614875913/en/
Ikonisys Alessandro Mauri CFO investors@ikonisys.com
NewCap Olivier Bricaud / Louis-Victor Delouvrier Investor
Relations Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 92
NewCap Nicolas Merigeau Media Relations
Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 98
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024